Related Experiment Video
Updated: Jul 6, 2026
Acute Myocardial Infarction in Rats
Published on: February 16, 2011
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril
S G Ball1, A S Hall, G D Murray
1Academic Unit of Cardiovascular Studies, University of Leeds, U.K.
Insights
Cardiomyocytes cannot regenerate, making heart attack damage permanent. Early aspirin and thrombolytic therapy reduce mortality, while ACE inhibitors show promise for heart failure patients, improving survival rates.
Area of Science:
- Cardiology
- Cell Biology
- Pharmacology
Background:
- Adult cardiomyocytes lack regenerative capacity, leading to permanent myocardial damage after infarction.
- Myocardial infarction significantly increases the risk of premature death.
- Early aspirin and thrombolytic therapy improve outcomes in myocardial infarction, but early heart failure remains a major concern.
Purpose of the Study:
- To review the impact of early interventions on myocardial infarction mortality.
- To evaluate the role of angiotensin-converting enzyme (ACE) inhibitors in managing heart failure post-myocardial infarction.
- To discuss the potential expansion of ACE inhibitor indications based on ongoing trials.
Main Methods:
- Review of recent clinical trials on myocardial infarction treatments.
- Analysis of data from the AIRE Study and SAVE Study regarding ACE inhibitor efficacy.
- Discussion of findings from the ISIS-4 and GISSI-3 trials.
Main Results:
- Immediate aspirin and thrombolytic therapy reduce short- and long-term mortality after myocardial infarction.
- Delayed initiation and long-term ACE inhibitor treatment significantly reduce all-cause mortality in selected heart failure patients or those with low ejection fraction.
- The precise mechanism of ACE inhibitor benefit is under investigation, possibly involving reduced myocyte death.
Conclusions:
- Early interventions like aspirin and thrombolytics are crucial for myocardial infarction management.
- ACE inhibitors offer significant survival benefits for specific post-myocardial infarction patient groups.
- Further research, including ISIS-4 and GISSI-3, is needed to determine broader clinical indications for ACE inhibitors.
Abstract:
Unlike most cell-types in the body, cardiomyocytes do not replicate in adult life. Consequently myocardial infarction produces irreparable damage to the heart which in turn increases the likelihood of premature death. Recent trials indicate that immediate aspirin and thrombolytic therapy beneficially modify the natural history of myocardial infarction, reducing both short- and long-term mortality rates. However, the occurrence of early heart failure in as many as one third of patients continues to carry with it a particularly poor prognosis. Recent trials with ACE inhibitors indicate that delayed initiation (beyond 24 h) and long-term maintenance treatment of patients selected on the basis of either heart failure (AIRE Study) or an ejection fraction of less than 40% (SAVE Study) result in large reductions in all-cause mortality. Although the exact mechanism of this benefit remains uncertain the reduction of further myocyte death due to reinfarction or gradual toxic attrition has been suggested. The currently unreported ISIS-4 and GISSI-3 should provide additional information as to whether the clinical indications for ACE-inhibitor therapy should be extended to other patient groups.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Atherosclerosis III: Management